These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 37633256)

  • 1. Chronic Hepatitis B Finite Treatment: Similar and Different Concerns With New Drug Classes.
    Peters MG; Yuen MF; Terrault N; Fry J; Lampertico P; Gane E; Hwang C; Stamm LM; Leus M; Maini MK; Mendez P; Lonjon-Domanec I; Berg T; Wang S; Mishra P; Donaldson E; Buchholz S; Miller V; Lenz O
    Clin Infect Dis; 2024 Apr; 78(4):983-990. PubMed ID: 37633256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference
    Cornberg M; Lok AS; Terrault NA; Zoulim F;
    J Hepatol; 2020 Mar; 72(3):539-557. PubMed ID: 31730789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial.
    Yuen MF; Asselah T; Jacobson IM; Brunetto MR; Janssen HLA; Takehara T; Hou JL; Kakuda TN; Lambrecht T; Beumont M; Kalmeijer R; Guinard-Azadian C; Mayer C; Jezorwski J; Verbinnen T; Lenz O; Shukla U; Biermer M;
    Lancet Gastroenterol Hepatol; 2023 Sep; 8(9):790-802. PubMed ID: 37442152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: Report from the 2022 AASLD-EASL HBV-HDV Treatment Endpoints Conference.
    Ghany MG; Buti M; Lampertico P; Lee HM;
    Hepatology; 2023 Nov; 78(5):1654-1673. PubMed ID: 37326326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients.
    Kao JH; Jeng WJ; Ning Q; Su TH; Tseng TC; Ueno Y; Yuen MF
    Hepatol Int; 2021 Aug; 15(4):833-851. PubMed ID: 34297329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How to achieve functional cure of HBV: Stopping NUCs, adding interferon or new drug development?
    Wong GLH; Gane E; Lok ASF
    J Hepatol; 2022 Jun; 76(6):1249-1262. PubMed ID: 35589248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Latest developments in the treatment of hepatitis B.
    Dandri M; Petersen J
    Minerva Gastroenterol Dietol; 2016 Mar; 62(1):88-102. PubMed ID: 26448309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic hepatitis B: a scoping review on the guidelines for stopping nucleos(t)ide analogue therapy.
    Hui RW; Mak LY; Seto WK; Yuen MF; Fung J
    Expert Rev Gastroenterol Hepatol; 2023 May; 17(5):443-450. PubMed ID: 36972516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A role for immune modulation in achieving functional cure for chronic hepatitis B among current changes in the landscape of new treatments.
    Laupèze B; Vassilev V; Badur S
    Expert Rev Gastroenterol Hepatol; 2023; 17(11):1135-1147. PubMed ID: 37847193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study).
    Liem KS; Fung S; Wong DK; Yim C; Noureldin S; Chen J; Feld JJ; Hansen BE; Janssen HLA
    Gut; 2019 Dec; 68(12):2206-2213. PubMed ID: 31462554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toward a complete cure for chronic hepatitis B: Novel therapeutic targets for hepatitis B virus.
    Kim SW; Yoon JS; Lee M; Cho Y
    Clin Mol Hepatol; 2022 Jan; 28(1):17-30. PubMed ID: 34281294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What will it take to cure hepatitis B?
    Jeng WJ; Lok ASF
    Hepatol Commun; 2023 Apr; 7(4):. PubMed ID: 36972391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Finite nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B: From an "option" to an "active recommendation".
    Liaw YF; Chien RN
    Kaohsiung J Med Sci; 2022 Apr; 38(4):295-301. PubMed ID: 35262284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Towards a Functional Cure for Hepatitis B Virus: A 2022 Update on New Antiviral Strategies.
    Degasperi E; Anolli MP; Lampertico P
    Viruses; 2022 Oct; 14(11):. PubMed ID: 36366502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stopping long-term treatment with nucleos(t)ide analogues is a favourable option for selected patients with HBeAg-negative chronic hepatitis B.
    van Bömmel F; Berg T
    Liver Int; 2018 Feb; 38 Suppl 1():90-96. PubMed ID: 29427489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism of interferon alpha therapy for chronic hepatitis B and potential approaches to improve its therapeutic efficacy.
    Zhao Q; Liu H; Tang L; Wang F; Tolufashe G; Chang J; Guo JT
    Antiviral Res; 2024 Jan; 221():105782. PubMed ID: 38110058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis B cure: From discovery to regulatory approval.
    Lok AS; Zoulim F; Dusheiko G; Ghany MG
    J Hepatol; 2017 Oct; 67(4):847-861. PubMed ID: 28778687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review article: hepatitis B-current and emerging therapies.
    Yardeni D; Ghany MG
    Aliment Pharmacol Ther; 2022 Apr; 55(7):805-819. PubMed ID: 35224760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update on hepatitis B virus infection.
    You CR; Lee SW; Jang JW; Yoon SK
    World J Gastroenterol; 2014 Oct; 20(37):13293-305. PubMed ID: 25309066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B.
    Rinker F; Zimmer CL; Höner Zu Siederdissen C; Manns MP; Kraft ARM; Wedemeyer H; Björkström NK; Cornberg M
    J Hepatol; 2018 Sep; 69(3):584-593. PubMed ID: 29758333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.